Do you already have an account on Campus Sanofi?
Explore latest events, medical insights and trends.
Up to 75% of RSV-associated hospitalisations occur in healthy and full-term children.2 Recent studies have shown that nirsevimab provided up to 90% protection against hospitalisation from severe RSV LRTI in infants during their first RSV season.3
In Singapore, RSV circulates all-year round and causes significant paediatric health and economic burden.2 This highlights the need and importance of RSV immunisation to reduce the burden of disease.2
RSV is the primary cause of LRTIs in children worldwide.2 Infants aged 3 months old have the highest risk of severe RSV LRTIs.2
Watch this to understand the challenges of managing COPD in primary care in Singapore.
May 17–21, 2025; San Francisco, California, US
